- Home
- QURE vs OPK Comparison
QURE vs OPK Comparison
Compare QURE & OPK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QURE
- OPK
- Stock Information
- Founded
- QURE 1998
- OPK 2007
- Country
- QURE Netherlands
- OPK United States
- Employees
- QURE N/A
- OPK N/A
- Industry
- QURE Biotechnology: Pharmaceutical Preparations
- OPK Biotechnology: Pharmaceutical Preparations
- Sector
- QURE Health Care
- OPK Health Care
- Exchange
- QURE Nasdaq
- OPK Nasdaq
- Market Cap
- QURE 866.3M
- OPK 1.0B
- IPO Year
- QURE 2007
- OPK 1995
- Fundamental
- Price
- QURE $14.16
- OPK $1.39
- Analyst Decision
- QURE Strong Buy
- OPK Buy
- Analyst Count
- QURE 11
- OPK 4
- Target Price
- QURE $39.91
- OPK $2.75
- AVG Volume (30 Days)
- QURE 1.1M
- OPK 2.0M
- Earning Date
- QURE 11-04-2025
- OPK 11-06-2025
- Dividend Yield
- QURE N/A
- OPK N/A
- EPS Growth
- QURE N/A
- OPK N/A
- EPS
- QURE N/A
- OPK N/A
- Revenue
- QURE $14,337,000.00
- OPK $664,029,000.00
- Revenue This Year
- QURE N/A
- OPK N/A
- Revenue Next Year
- QURE $288.08
- OPK $0.84
- P/E Ratio
- QURE N/A
- OPK N/A
- Revenue Growth
- QURE N/A
- OPK N/A
- 52 Week Low
- QURE $4.45
- OPK $1.11
- 52 Week High
- QURE $19.18
- OPK $2.04
- Technical
- Relative Strength Index (RSI)
- QURE 34.28
- OPK 51.88
- Support Level
- QURE $17.03
- OPK $1.34
- Resistance Level
- QURE $17.76
- OPK $1.44
- Average True Range (ATR)
- QURE 0.95
- OPK 0.04
- MACD
- QURE -0.39
- OPK -0.00
- Stochastic Oscillator
- QURE 3.13
- OPK 50.00
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
About OPK OPKO Health Inc.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.